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Summary It has been suggested that sensitivity of ovarian carcinomas to cisplatin is in part related to an endogenous folate deficiency. In
this work, we investigated whether overexpression of the folate-binding protein (FBP), a receptor involved in folate transport, might be
associated with cisplatin sensitivity. The results obtained on a panel of ten ovarian carcinoma cell lines that overexpress different levels of the
FBP showed a statistically significant relationship between FBP overexpression and cisplatin responsiveness, with the most sensitive cell
lines expressing higher FBP levels on their membrane than the less sensitive ones. The relationship was observed both in cells growing in
standard medium-containing high- folate concentrations (2.3gM) and in cells adapted to growth in low-folate (20 nM) medium. Analysis of two
cisplatin-resistant cell lines derived from the cisplatin-sensitive IGROV1 ovarian carcinoma cell line indicated that resistance was associated
with a significant decrease in FBP expression. However, the receptor does not appear to be directly responsible for drug sensitivity per se as
different cell lines transfected with FBP cDNA did not become more sensitive to the drug. Together, the data suggest the possible predictive
value of FBP in ovarian carcinoma, as higher levels of expression can be indirectly but significantly associated with increased drug sensitivity.
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Platinum-derived compounds have occupied a dominant place
in cancer therapy, particularly for the treatment of ovarian malig-
nancies (Rosenberg, 1985; Ozols, 1992). Unfortunately, not
all tumours are responsive, and initially sensitive tumours
often become resistant in a short time (Andrews et al, 1990;
Ozols et al, 1991).
Various mechanisms have been proposed to contribute to
cisplatin resistance, including altered drug accumulation (Loh et
al, 1992; Nakagawa et al, 1993; Jekunen et al, 1994; Misawa et al,
1995), enhanced drug detoxification by elevated metallothionein
or glutathione levels (Andrews et al, 1987; Morrow et al, 1990;
Tedeschi et al, 1990; Mistry et al, 1991), enhanced DNA repair
capability (Masuda et al, 1988; Eastman et al, 1988) or up-
regulation of specific biochemical pathways (Andrews and
Howell, 1990). Concerning, in particular, the last possibility, an
association between cisplatin resistance and changes in folate
metabolism has been observed. Indeed, cisplatin can stimulate
endogenous methionine and folate metabolism (Gross et al, 1986;
Shionoya et al, 1986; Scanlon et al, 1989a). Enhanced 5,10-meth-
ylenetetrahydrofolate (5,10-methylene THF) and THF pools and
enhanced gene expression of enzymes of the dTMP synthase
cycle, which is the sole source of de novo dTMP, have been
observed in drug-resistant cells (Scanlon et al, 1986, 1988, 1989b;
Newman et al, 1988; Lu et al, 1988). For example, A2780 human
ovarian carcinoma cells selected for cisplatin resistance have
elevated mRNA and enzyme activity for dTMP synthase cycle
enzymes, such as dihydrofolate reductase, thymidylate synthase
and thymidine kinase (Scanlon et al, 1988), thus suggesting that
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increased dTMP synthase activity might be required for the repair
ofcisplatin-induced DNA damage.
Previous reports have shown that the 38-KDa folate-binding
protein (FBP) is overexpressed in a majority of non-mucinous
ovarian carcinomas (Miotti etal, 1987; Campbell etal, 1991; Coney
et al, 1991) and this folate receptor is directly involved in cellular
internalization of folate compounds (Henderson, 1990; Antony,
1992). Its increased expression in ovarian carcinomas, the cause of
which has not yet been determined, raises intriguing questions
about a possible altered folate metabolism in these tumour cells.
5-MethylTHF, the principal form of folate in serum, can be
internalized into cells through the FBP but can also be obtained by
the reduction of5,10-methylene THF catalysed by methylene THF
reductase. There is preliminary evidence to indicate that the
methylene THF reductase gene is frequently deleted in ovarian
carcinomas (Dall'Agnese et al, 1995), raising the possibility that
the cells overcome the decreased internal concentration of
5-methylTHF by overexpressing the external FBP receptor.
In the present study, we investigated whether the different levels
of FBP expression found in ovarian carcinoma cell lines, which
might reflect alterations in the folate metabolism, are predictive of
tumour cell responsiveness to cisplatin treatment.
MATERIALS AND METHODS
Cells and culture conditions
The following human ovarian carcinoma cell lines were used in this
study: OVCAR3 (Dr I Pastan, NIH, Bethesda, MD, USA),
IGROVI (Dr J Benard, Institute G Roussy, Villejuif, France),
OVCA432 (Dr R Knapp, Dana Farber Institute, Boston, MA,
USA), OVCAR4 and OVCAR5 (Dr R Camalier, NCI, Frederick,
MD, USA), SKOV3 and CAOV3 (ATCC, Rockville, MD, USA),
SW626 (Memorial Sloan-Kettering Cancer Center, New York, NY,
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USA), DP-pol (recently established from metastatic cystoadenocar-
cinoma of the ovary by Dr V Ramakrishna, Istituto Nazionale
Tumori, Milan, Italy), CABAl (recently established from cells
recovered from ovarian carcinoma ascitic fluid by Dr V Dolo,
University of L'Aquila, L'Aquila, Italy). All cell lines were
cultured in standard RPMI-1640 medium (2.3gM folic acid) (Irvine
Scientific, Santa Ana, CA, USA). Some of these cell lines were
also maintained in low-folate medium (L-RPMI) containing 20 nm
folic acid (Gibco BRL-Life Technologies, Paisley, UK), as
described (Miotti et al, 1995), and were designated L-IGROV1, L-
OVCA432, L-OVCAR4, L-SKOV3 and L-SW626. These cells
were grownbriefly in folate-free medium before cytotoxicity assay.
Transfected L-SKOV3, Chinese hamster ovary (CHO) and
NIH/3T3 (Bottero et al, 1993) cells were maintained in L-RPMI,
standard RPMI-1640 and standard Dulbecco's modified Eagle
medium containing 9.2 gM folate (Boehringer-Mannheim,
Germany), respectively, in the presence of 800 gg ml-' of
geneticin G418 (GIBCO).
All media were supplemented with 5% or 10% heat-inactivated
fetal calfserum (FCS), 2 mM L-glutamine, 100 units ml-1 penicillin
and 100 gg ml' streptomycin. IGROV1/Pt 0.5 and IGROV1/Pt 1,
two cisplatin-resistant sublines ofIGROV1, were kindly provided
by DrFZunino (Istituto Nazionale Tumori, Milan). These sublines
were selected by continuous exposure of cisplatin-sensitive
IGROV1 cells to increasing drug concentrations and were main-
tained in medium containing 0.5 ,ug ml-' and 1 ,ug ml-' cisplatin
(Platinex, Bristol Italiana, Sermoneta, Latina, Italy).
Evaluation of cisplatin-induced cytotoxicity
A colorimetric assay based on 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was used to measure cytotoxi-
city. Briefly, 1 x 104 tumour cells per well were seeded in 96-well
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Figure 1 Cisplatin-induced cytotoxicity in 10 human ovarian carcinoma cell
lines. Cells grown in standard RPMI medium were exposed, immediately
after seeding, to different drug concentrations for 48 h at 370C. Per cent cell
survival, evaluated by MTT assay (see Materials and methods), was
calculated as the ratio between the OD at each dose of the drug and the OD
of the untreated control x 100. Data points and IC50 represent the mean
values of three separate experiments
plates and immediately incubated for 48 h at 370C with serial dilu-
tions ofcisplatin starting from 200 ,UM. Cells grown in L-RPMI were
seeded at 2500 or 5000 cells per well and, during the exponential
growth phase (4-7 days from plating, depending on the cell line),
incubated with serial dilutions of cisplatin as above. MIT
[5 mg ml' in sterile phosphate-buffered saline (PBS)] was added
(20 ,l per well) and plates were incubated for 3 h at 37°C. Plates
were then centrifuged and the supernatant was removed. Cells in
each well were solubilized with isopropanol and absorbance at
550 nm was measured. Cytotoxicity was expressed as per cent
surviving cells in treated cultures compared with untreated controls.
The IC50 value represents the cisplatin concentration that inhibits cell
growth by 50% compared with controls incubated without the drug.
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Figure 2 Correlation between cisplatin-induced cytotoxicity and FBP expression in ovarian carcinoma cell lines. Cells grown in RPMI standard medium (A)
were tested immediately after seeding; cells grown in low-folate medium (B) were tested 4-7 days after seeding. IC50 values obtained by MTT assay were
plotted against fluorescence units for each cell line. Each curve is a linear regression fit
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Figure 3 FBP expression on IGROV1 cells and their cisplatin-resistant variants IGROV1/Pt 0.5 and IGROV1/Pt 1. Binding reactivities of (A) MOvl8 (anti-FBP);
(B) W6/32 (anti-HLA class l); (C) MINT5 (anti-EGFR); and (D) MGR3 (anti-HER-2/neu) were analysed by indirect immunofluorescence assay and flow
cytometry. parental IGROVI; - - -, IGROV1/Pt 0.5; -, IGROV1/Pt 1; - - -, unstained cells
Vector construction and transfection
The human FBP cDNA, cloned into the pcDNAI/neo vector as
described (Bottero et al, 1993), was used to transfect CHO
(Bottero et al, 1995) and L-SKOV3 cells using the lipofectin tech-
nique. Briefly, cells were harvested by trypsinization and replated
at a density of 1.5 x 104 per well in 96-well plates in their respec-
tive medium plus 5% FCS. Plates were incubated at 37°C until the
cells were about 40% confluent (after 18-24 h). After washing the
plates, cells were incubated in medium without FCS and 3 h later,
6 jig of either the vector containing the human FBP cDNA or the
vector alone, plus 10 gg oflipofectin diluted in 0.9% sodium chlo-
ride, was added to the cells (designated FBP-tL-SKOV3, FBP-
tCHO and MOCK-t). After 24 h, the medium was replaced with
fresh medium containing 10% FCS and after an additional 24 h,
geneticin G418 sulphate (Gibco) was added. Selection was carried
out for 4-5 days and surviving clones were tested by indirect
immunofluorescence with monoclonal antibody (MAb) MOvl8,
which detects FBP (Miotti et al, 1987).
MAbs and indirect immunofluorescence assay
The following MAbs were used: anti-FBP MOv18; MINT5 (Tosi
et al, 1995), which specifically detects the epidermal growth factor
receptor (EGFR); MGR3 (Tagliabue et al, 1991), produced against
the HER-2/neu extracellular domain and W6/32 (ATCC,
Rockville, MD, USA), detecting HLA class I molecules.
British Journal ofCancer (1997) 76(1), 77-82
A
FBP expression and cisplatin sensitivity 79
0
0 .0
E
z
102 i03 104 Ib4
.Cancer Research Campaign 199780 F Ottone etal
Table Observed and expected cisplatin-induced toxicity in three different
FBP-transfected cell lines
Fluorescence units Observed Expected
IC50(gM) IC50 (gM)
FBPt L-SKOV3 90 000 36 2.3
MOCKt L-SKOV3 15 000 12.5 10
FBPt CHO 10 400 25 2.6
MOCKt CHO 1400 16 -
FBPt NIH/3T3 17 000 2 0.1
MOCKt NIH/3T3 800 2.5 -
The expected IC50 values were extrapolated from the regression rate of each
cell line based on their FBP expression (see text) as evaluated by
immunofluorescence assay using MOv18 MAb.
Indirect immunofluorescence assay was carried out as described
(Miotti et al, 1992). Briefly, cells harvested by trypsinization were
incubated with primary MAb (10 ,ug ml-' of purified MAbs or
ascitic fluid diluted 1:100) for 30 min at 37°C and, after two wash-
ings in PBS-5% FCS, incubated for an additional 30 min on ice
with fluorescein-labelled goat anti-mouse Ig. Cells were washed
twice, resuspended in cold PBS and analysed by FACScan. Cells
incubated with fluoresceinated antibody only were included as a
control for background staining.
Specific staining was determined by subtracting the relevant
control histogram. Total fluorescence was expressed as fluores-
cence units obtained by multiplying mean fluorescence of specifi-
cally stained cells by the number ofpositive cells.
RESULTS
Cisplatin sensitivity of 10 ovarian carcinoma cell lines grown in
RPMI-1640 standard medium was investigated using the MTT
assay. Dose-response curves obtained after 48-h exposure ofcells
to cisplatin (Figure 1) revealed IC50 values of 3.5-5 gM in three
cell lines (DP-pol, CAOV3 and CABAl), 6.8-9.7 ,UM in four cell
lines (OVCAR3, IGROVI, OVCA432 and OVCAR4) and
15.2-46 ,UM in three cell lines (SKOV3, OVCAR5 and SW626).
Indirect immunofluorescence assay of FBP expression on the
same cell lines using MAb MOv18 indicated a wide range of
expression levels (fluorescence units of 1150 in OVCAR5 cells to
38 000 in OVCAR3 cells), which correlated significantly (r =
0.68; P = 0.027) with cisplatin sensitivity when IC50 values were
plotted against fluorescence units (Figure 2A). Cisplatin sensi-
tivity remained unchanged when two cell lines were grown in low-
folate medium (L-IGROV1, IC50 = 9.3 ,UM; L-SKOV3, IC50 =
17.5 gM). In order to associate conditions oflimited external folate
availability (L-RPMI) to enhanced folate requirement (prolifera-
tion), actively proliferating L-RPMI cells were tested. By plotting
IC50 values against fluorescence units for L-IGROV1, L-
OVCA432, L-OVCAR4, L-SKOV3 and L-SW626 (Figure 2B),
the same positive relationship between FBP expression and
cisplatin sensitivity (r = 0.85; P = 0.066) was observed. Note that
the difference between the IC50 values of the more sensitive cell
lines (L-IGROVl, L-OVCA432, and L-OVCAR4) and the more
resistant cell lines (L-SKOV3 and L-SW626) appeared to be
enhanced.
Two cisplatin-resistant variants of IGROV1, a cell line which
expresses high levels of FBP, were selected following continuous
exposure to cisplatin. The two sublines, IGROV1/Pt 0.5 and
IGROV1/Pt 1, were 5 and 10 times more drug resistant than the
parental cell line, with IC50 values of 35 and 72 gM respectively.
The immunofluorescence staining pattern of MOv18 on these cell
lines (Figure 3A) indicated a cisplatin dose-dependent decrease in
FBP expression levels; IGROV1/Pt 1 cells showed a single peak
with a lower mean fluorescence than that of the parental cells,
whereas IGROV1/Pt 0.5 cells showed two peaks, one which
included about 30% of the cells, with a mean fluorescence value
similar to that ofthe parental cells, and the other which was super-
imposible on the peak corresponding to the more resistant
IGROV1/Pt 1 subline. Similar analyses using anti-HLA MAb
W6/32 and anti-EGFR Mab MINT5 revealed no substantial differ-
ences between the parental and the variants in expression of these
molecules (Figure 3B and C respectively), whereas reactivity of
MAb MGR3, which detects the extracellular domain of HER-
2/neu, indicated that the level of protein was higher in the
cisplatin-resistant variants than in the parental cells (Figure 3D).
To examine whether cisplatin sensitivity is a direct consequence
of FBP overexpression, both parameters were evaluated in
NIH/3T3, CHO and L-SKOV3 cells transfected with a recombi-
nant plasmid vector containing FBP cDNA (Table). Transfected
cells expressed from 6 to 20 times more FBP on the membrane
than cells transfected with the empty vector (mock transfected).
The IC50 values expected on the basis of FBP expression were
extrapolated from the regression rate of each cell line (for FBP-t
and MOCK-t L-SKOV3 cells, directly from the regression rate
reported in Figure 2a and, for FBP-t CHO and NIH/3T3, from a
straight line with the same slope and passing through the point
identified by the intersection of fluorescence units and IC50 values
of the respective mock-transfected cells) and compared with IC50
values observed for each transfected and control cell line. FBP-
transfected cells were not more sensitive to cisplatin, and the IC50
values of transfected L-SKOV3 and CHO cells were only three-
and 1.5-fold higher, respectively, than in their mock-transfected
counterparts, whereas transfected NIH/3T3 cells showed the same
IC50 as the mock-transfected cells.
DISCUSSION
Our studies reveal a correlation between FBP expression and
cisplatin sensitivity in ovarian carcinoma cell lines, although the
relationship between the two parameters is probably indirect as
overexpression ofthe folate receptor on cells transfected with FBP
cDNA did not increase the drug sensitivity. As drug resistance is
associated with low FBP expression, cisplatin sensitivity of
ovarian tumours might be an indirect consequence of the event
that induces these cells to overexpress FBP.
The mechanism responsible for FBP overexpression in ovarian
carcinomas remains unknown. No gene amplification has been
found so far (Foulkes et al, 1993), indicating that regulation of
FBP is likely at the transcriptional level. There is evidence to
suggest that the response to cisplatin might be dependent on folate
deficiency (Branda et al, 1993). A correlation has been observed
between cisplatin cytotoxicity and the requirement for exogenous
folate. In particular, it has been demonstrated that relatively resis-
tant human carcinoma cell lines require lower exogenous concen-
trations of folinic acid for growth (Scanlon et al, 1989a). Thus, a
cell line that relies more on endogenous folate metabolism than on
exogenous contributions may be less sensitive to the cytotoxic
effects of cisplatin. Consequently, FBP overexpression might be
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an external signal ofan internal deficiency ofthe cell in the use of
folates, and this deficiency might have relevance in the cellular
response to cisplatin as increased levels of enzymes involved in
dTMP cycle are needed for DNA repair.
In our experiments in which the ovarian carcinoma cell lines
were cultured at high (2.3 gM) extracellular folate concentrations
(Figures 1 and 2A), folate presumably enters the cells by passive
diffusion, independent of the level of FBP expression (Antony et
al, 1989). Because these culture conditions ensured adequate
delivery of folate to all cell lines used, the differential cisplatin
responsiveness cannot be attributed to different availability of
endogenous folates but instead might reflect differences in the
capacity to use them. FBP expression levels have been reported to
be inversely regulated by the extra- and intracellular folate concen-
tration (Kamen et al, 1986; Kane et al, 1988) but, in our hands,
only one (L-SKOV3) out of five ovarian carcinoma cell lines
tested showed FBP up-modulation when adapted at physiological
folate concentrations (20 nM) (Miotti et al, 1995). In the same
study, all the cell lines showed a marked decrease in endogenous
folates compared with cells grown in standard medium (2.3 ,UM),
and the amount of total folate in the cells was in general directly
proportional to the level of membrane FBP expression, consistent
with the concept that intracellular folate content is maintained
primarily by FBP in low-folate cultured cells (Matsue et al, 1992).
Growth in low-folate medium did not change the cisplatin sensi-
tivity of IGROVI and SKOV3 cells in our study. Moreover, the
results obtained with proliferating cells under low-folate condi-
tions (Figure 2B) further support the notion that cell lines with
higher FBP expression are more sensitive to cisplatin treatment. In
addition, the differences among the IC50 values of sensitive and
resistant cells were enhanced. In particular, SKOV3 and SW626
cells became even more cisplatin-resistant than the other lines.
Together, these results are in agreement with the hypothesis that
low-FBP, cisplatin-resistant cells use endogenous folates more
effectively than high-FBP, cisplatin-sensitive cells.
Whereas FBP transfection of cell lines that presumably have
normal folate metabolism (NIH/3T3 and CHO) or that are charac-
terized by expression of low levels of FBP (L-SKOV3) did not
result in a lowerIC50, the two cell lines ofepithelial origin became
more resistant than the respective mock-transfected cells (Table).
These data support the notion that it is not FBP expression levels
per se that underlie the cell response to cisplatin. However, the
possibility exists that overexpression ofFBP in plasma membrane
of transfected cells reduced uptake of cisplatin, thus reducing the
sensitivity ofthe cell lines to the drug.
Our analysis of the two cisplatin-resistant variants of IGROV1
cells confirms the inverse relationship between the degree ofresis-
tance and the number of FBP receptors (Figure 3A). This finding
suggests that cisplatin treatment selects for cells that require only
minimal FBP expression on the membrane for survival. This
decreased FBP expression appears to be specific as other markers
(Figure 3B, C and D) remained essentially unchanged or increased
compared with parental cells. It has to be noted that the increased
expression of HER-2/neu on resistant cells is consistent with
previous observations, suggesting the cisplatin resistance ofHER-
2/neu-positive tumours in vivo (Berchunck et al, 1990). Thus, the
in vitro selection procedure appears to result in cisplatin-resistant
cells that reflect the in vivo situation.
The results of our study suggest the potential interest of FBP
expression as a predictive factor in the outcome of ovarian carci-
noma treatment with cisplatin, as higher levels of expression were
significantly associated with more effective drug responsiveness.
In addition, the data on the IGROVI-derived cisplatin-resistant
cell lines suggest that cisplatin therapy can select for subpopula-
tions ofintrinsically drug-resistant tumour cells characterized by a
lower FBP expression than the original tumour.
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